<DOC>
	<DOCNO>NCT02704702</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety Fimasartan rosuvastatin coadministered administered alone single dose multiple dos healthy male subject .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Pharmacokinetics Safety Fimasartan Rosuvastatin Healthy Male Subjects</brief_title>
	<detailed_description>This open-label , randomize , 6-sequence , 3-period , 3-way crossover study . Within period , randomized subject 2 dose regimen drug ( fimasartan rosuvastatin ) study drug combination ( fimasartan+rosuvastatin ) day 1 quaque die ( qd ) day 4 day 10 . After day 1 day 10 dosing follow pharmacokinetic sample 48 hour 72 hour .</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Caucasian male 1955 year age . 2 . Body mass index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 screening . 3 . Medically healthy clinically significant medical history . 4 . Understands study procedure Informed consent form ( ICF ) , willing able comply protocol . 1 . History presence clinically significant medical psychiatric condition disease . 2 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) . 3 . Seated blood pressure le 90/60 mmHg great 140/90 mmHg screening . 4 . Plasma donation within 7 day prior first dose study drug . 5 . Participation another clinical trial within 28 day prior first dose study drug ( ) .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>